Pulmonary gene therapy with nonviral vectors delivered by instillation or intravenously has typically been associated with co-induction of cytokine responses attributed to the CpG motifs in the bacterial plasmid. Alternative delivery systems are being developed to circumvent the cytokine responses to the plasmid. Aerosol delivery of polyethylenimine-DNA (PEI-DNA) complexes leads to localized, high levels of transgene expression in the lungs. In this study, we show that PEI-DNA aerosol delivery is also associated with induction of tumor necrosis factor alpha (TNF-␣) and interleukin 1 beta (IL-1␤) in the lung and bronchoalveolar lavage fluid (BALF). However, there is no increase in the serum levels of these cytokines. The levels of these cytokines peak at 5-8 h after aerosol exposure for lung tissue,
Different routes for gene delivery have been investigated for targeting various organs. The lungs, which are a major organ of interest for gene delivery, have been targeted mainly through intravenous, intratracheal or nasal instillation. [1] [2] [3] Recently, gene delivery by these routes, using cationic lipid-DNA complexes, has been shown to result in immune and cytokine responses in mice. [4] [5] [6] [7] [8] Bacterial plasmids contain unmethylated CpG motifs, which can trigger potent cytokine and B-cell responses and also enhance the activity of NK cells. [9] [10] [11] [12] Furthermore, it has been shown that DNA or cationic lipid alone does not induce high levels of cytokines, however, cationic lipid-DNA complexes induce very potent cytokine responses. [4] [5] [6] An alternative approach to target the lungs is through aerosol delivery of genes. 13 We have previously shown that aerosol delivery of PEI-DNA complexes results in a higher transgene expression in the lungs as compared with different cationic lipids tested. 14 We optimized the aerosol delivery of PEI-DNA complexes to achieve high and persistent levels of transgene in the lungs and have shown that the delivery has a therapeutic effect in an experimental lung metastasis model using the p53 tumor suppressor gene. 15, 16 In the present study, we wanted to investigate whether aerosol delivery of PEI-DNA complexes to mice leads to any cytokine response as pre- and at 24 h for BALF. However, the levels detected are much lower than those observed when PEI-DNA complexes, guanidinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA (BGTC:DOPE-DNA) complexes or 1 , 2 -dioleoyl -sn -glycero-3 -trimethylammonium -propanecholesterol:DNA (DOTAP-Chol:DNA) complexes were delivered intravenously. Also, the lung cytokine levels were higher when BGTC:DOPE-DNA complexes were delivered by aerosol to the mice. Although the mechanism remains to be elucidated, the data suggest that aerosol exposure to PEI-DNA complexes can achieve high levels of transgene expression in the lungs without inducing high levels of cytokine responses. Gene Therapy (2001) 8, 254-257.
viously reported for instillation or intravenous delivery of cationic lipid-DNA complexes.
The cytokine response to intravenous or instillation delivery of cationic lipid-DNA complexes has been well documented and has also been shown to decrease the levels of transgene expression. [4] [5] [6] [7] [8] To investigate if a similar pattern is observed for aerosol delivery of PEI-DNA complexes, mice were exposed to PEI-DNA aerosol complexes (25 kDa branched PEI; Aldrich Chemicals, Milwaukee, WI, USA; complexes prepared as described in Ref. 14; the PEI nitrogen:DNA phosphate (N:P) ratio can be determined by taking into account the fact that 1 g of DNA has 3 nmol of phosphate and 1 l of 0.1 m PEI solution has 100 nmol of amine nitrogen, and 10:1 N:P ratio corresponds to 1.29:1 PEI:DNA weight ratio). A plasmid containing the p53 gene under the control of the cytomegalovirus promoter (pCMVp53) was used. The plasmid was purified by Bayou Biolabs (Harahan, LA, USA) and was endotoxin free. Mice exposed to BGTC:DOPE-pCMVp53 aerosol complexes (Avanti Polar Lipids, Alabaster, AL, USA; complexes prepared as described in Ref. 17) , or injected intravenously with DOTAP-Chol:pCMVp53 complexes (Avanti Polar Lipids; complexes prepared as described in Ref. 4) , BGTC:DOPEpCMVp53 complexes or PEI-pCMVp53 complexes, were used for comparison. BGTC:DOPE, rather than DOTAPChol was used for aerosol delivery of DNA, since BGTC:DOPE can protect the DNA more effectively during nebulization. 14, 17 The dosage was 5 g of DNA (in 200 l) per mouse for intravenous injections; and for aerosol a total of 2 mg of DNA/10 ml solution was aero-solized to the mice (estimated to deliver approximately 5 g DNA to the lungs 15 ). The aerosol was delivered as previously described. 15 At different time-points after exposure, the mice were bled from the abdominal aorta and the blood was collected. The blood was incubated at room temperature for 2 h and then centrifuged at 14 000 g for 10 min. Serum was collected and frozen at −80°C until further assay. Broncheoalveolar lavage fluid (BALF) was also collected from the mice. The trachea was exposed by making a thin incision, cannulated endotracheally, and lavaged with 2 ml of Hank's balanced salt solution (HBSS, Ca 2+ /Mg 2+ free). The lungs were washed five times and the solution collected and frozen at −80°C. The lungs were also harvested after perfusion through the heart, and homogenized with a Wig-L-Bug (Crescent Dental Mfg., Lyons, IL, USA) bead homogenizer using 1 ml of ice-cold extraction buffer (50 mm Tris, pH 8, 150 mm Nacl, 1 mm EDTA, 0.5% Triton X-100, 1 m pepstatin A, 0.25 mm PMSF and 10 m leupeptin). The homogenate was centrifuged and the supernatant frozen at −80°C until further use. Samples from naive mice were used as controls. All procedures on mice were performed under anesthesia. Immunoassays were performed using murine-specific immunoassay kits for TNF-␣ and IL-1␤ (R&D Systems, Minneapolis, MN; Endogen, Woburn, MA, USA). The total protein content in the lungs was determined using the BCA protein assay (Pierce, Rockford, IL, USA).
Serum, lung tissue and BALF was initially analyzed for TNF-␣ and IL-1␤ at 2 h after exposure, since this was previously reported to be the peak expression interval for the induction of these cytokines after intravenous delivery of cationic lipid-DNA complexes. 4, 9 The levels of these cytokines 2 h after exposure were lowest for PEI-DNA aerosol exposed mice (Figures 1 and 2 that aerosol delivery of PEI-DNA complexes may not induce high levels of cytokines as observed after intravenous delivery of vector-DNA complexes. Next, we analyzed the kinetics of cytokine induction after PEI-DNA aerosol delivery in the lungs, serum and BALF. The levels of these cytokines in the lungs peaked at 5-8 h after aerosol exposure to PEI-DNA complexes, and were reduced to background levels after 24 h (Figure 3) . Furthermore, the peak cytokine level in the lungs was lower than that induced after intravenous delivery of cationic vector-DNA complexes (Figures 1 and 3) . The levels of TNF-␣ and IL-1␤ in the BALF peaked at 24 h and was resolved to control levels within 48 h after aerosol exposure (Figure 4) . The difference in the kinetics of cytokine induction in the lungs and BALF could be due to the fact that these cytokines are secreted, and thus were detected in the BALF at a later time-point. Furthermore, the induction of these cytokines seems to be restricted to the lungs and BALF, since there was no significant increase in the serum levels at any of the time-points evaluated. Similar results were obtained when an 'empty' vector PEI-pCMVNeobam (the same plasmid as pCMVp53 but without the p53 gene) and PEI-pCMVCAT (see below) were aerosolized to the mice. Also, PEI alone did not induce any significant levels of cytokines when delivered by aerosol (data not shown). The BALF was also evaluated for any inflammatory cell infiltration by cytochemical staining at different time-points (5, 24 and 48 h) after aerosol delivery. There was no neutrophil infiltration into the BALF at the time-points evaluated (data not shown), suggesting that the levels of cytokines in the BALF detected may not be high enough to stimulate an acute inflammatory response.
In order to compare the levels of transgene expression in the lungs, a plasmid containing the chloramphenicol acetyl transferase (CAT) gene under the control of the cytomegalovirus (pCMVCAT) promoter was used. The plasmid was purified by Bayou Biolabs and was endotoxin free. Mice were exposed to PEI-pCMVCAT or BGTC-DOPE:pCMVCAT aerosol complexes, or injected through the lateral tail vein with PEI-pCMVCAT or DOTAP-Chol:pCMVCAT complexes. The dose of DNA was 5 g (in 200 l) per mouse for intravenous injections, and for aerosol a total of 2 mg DNA/10 ml solution was delivered to the mice. 15 Twenty-four hours after exposure, mice were killed, the lungs harvested, homogenized and assayed for CAT activity using a CAT ELISA kit (Boehringer Mannheim, Indianapolis, IN, USA). As shown in Figure 5 , the levels of CAT detected in the lungs were highest for the PEI-DNA aerosol delivery (P Ͻ 0.05, PEI-CAT aerosol versus other groups, Student's t test). However, it should be noted that we delivered just 5 g of DNA intravenously, since that is the amount of DNA we estimate is deposited in the lungs after PEI-DNA (2, 5, 8, 12, 24 aerosol delivery. 15 However, other groups have reported higher levels of transgene expression in the lungs than that which we report here (by intravenous injection), when higher amounts of DNA were delivered intravenously. 1, 3 Furthermore, the levels of cytokines induced after aerosol delivery of CAT were similar to those observed when p53 was delivered by aerosol (4.67 ± 1.08 pg/mg protein TNF-␣ and 4.12 ± 0.978 pg/mg protein IL-1␤ for lungs, and 58.67 ± 4.89 pg/ml TNF-␣ and 31.23 ± 4.02 pg/ml IL-1␤ for BALF at 24 h time-point; with insignificant levels in the serum) which is lower than that observed for intravenous delivery of vector-DNA complexes, indicating that aerosol delivery leads to increased transgene expression in the lungs with minimal cytokine response.
Figure 4 Kinetics of TNF-␣ and IL-1␤ induction in BALF after aerosol delivery of PEI-DNA complexes. Two milligrams of pCMVp53 plasmid were complexed with PEI at a N:P ratio of 10:1 and aerosolized to female C57BL/6 mice (8 to 9-weeks old). Mice were killed at different time-points
Gene delivery to the lung using nonviral vectors holds promise for a variety of pulmonary diseases. However, the rapid decline in transgene expression and the refractory period (time interval between two consecutive exposures for similar transgene expression) between successive doses pose major challenges for gene therapy. Intravenous and other routes of gene delivery have been investigated for targeting the lungs. We have previously shown that aerosol delivery of PEI-DNA complexes leads to a high and persistent gene expression in the lungs, and also has an antitumor effect in a lung metastasis model. 15, 16 Also, we have shown that aerosol delivery of PEI-DNA complexes can elicit an antibody response for genetic immunization.
14 Here, we evaluate the cytokine responses associated with aerosol delivery of PEI-DNA complexes.
Induction of cytokine response to cationic lipid-DNA complexes is also a major challenge for gene therapy. Intravenous as well as instillation of cationic lipid-DNA complexes leads to a strong cytokine response in mice, [4] [5] [6] [7] [8] leading to reduced transgene expression and contributing to the refractory period between consecutive doses. 4, 9 In this study, we show that aerosol delivery of PEI-DNA complexes is also associated with a cytokine response, as that observed with intravenous or intratracheal administration of cationic lipid-DNA complexes. However, the levels of TNF-␣ and IL-1␤ induced after aerosol delivery of PEI-DNA complexes in the lung tissue, serum and BALF is much lower than those induced after intravenous delivery of cationic vector-DNA complexes. Moreover, we injected only 5 g of DNA intravenously. The levels of cytokines induced are dramatically increased when higher amounts of DNA are delivered intravenously or by instillation. 4, 7, 8 The amount of PEI-DNA aerosol delivered in this study has been shown to have a therapeutic effect in a lung metastasis model. 16 Here, we show that the therapeutic dose does not induce high levels of cytokines after single aerosol exposure. Furthermore, the refractory period reported between consecutive doses. 4, 9 for intravenous delivery, seems to be reduced for PEI-DNA aerosol delivery (Densmore et al, manuscript in preparation). We are currently evaluating the toxicity profile and induction of other cytokines such as IL-12, IFN-␥ and GM-CSF after repeated aerosol exposures to PEI-DNA.
The reduced cytokine response to the plasmid seems to be, in part, due to PEI, since aerosol delivery of BGTC:DOPE-DNA complexes induced significant levels of cytokines in the lungs and serum. However, it should be noted that intravenous delivery of PEI-DNA complexes also induces high levels of TNF-␣ and IL-1␤. It is possible that the combination of delivering DNA with PEI by aerosol leads to the reduction of cytokine response. Our data show that aerosol delivery of PEI-DNA complexes may potentially overcome the problem of cytokine responses associated with the plasmids when delivered in cationic liposomal formulations, 5, 7, 8 while leading to persistent and high levels of transgene expression in the lungs. PEI-DNA aerosol mode of delivery provides an attractive alternative to cationic liposome and viral vectors for gene delivery to the lungs.
The mechanism by which aerosol delivery of PEI-DNA complexes might lead to reduced cytokine responses is still unknown. A possible explanation could be that after aerosol delivery, PEI might be releasing the DNA slowly, which could result in a reduced cytokine response to the plasmid, whereas intravenous injection could lead to immediate or faster release of DNA from PEI due to interactions with serum proteins. The same could be the case for intravenous delivery of cationic liposome-plasmid formulations leading to a potent cytokine response. Also, the differences in cytokine induction could be simply due to the difference in the mode of delivery.
In this article we have shown that the levels of cytokines induced after PEI-DNA aerosol delivery are much lower than those observed by the intravenous route of gene delivery. This may be useful when a cytokine response to gene delivery is not desired in a clinical setting, such as for cystic fibrosis, alpha-1 antitrypsin deficiency and pulmonary hypertension.
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